If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and industries.Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.What if you'd invested in Halozyme Therapeutics (HALO) ten years ago? It may not have been easy to hold on to HALO for all that time, but if you did, how much would your investment be worth today?Halozyme Therapeutics' Business In-DepthWith that in mind, let's take a look at Halozyme Therapeutics' main business drivers.San Diego, CA-based Halozyme Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company also licenses its novel drug delivery technology, ENHANZE, for subcutaneous (SC) administration of drugs.The company’s ENHANZE drug delivery technology helps in developing the SC formulation of drugs. Several companies, including Roche, Takeda, J&J, AbbVie, Lilly, Bristol-Myers and others, are using this technology for developing the SC formulation of their currently marketed drugs. It also recognizes revenues from the sale of drug products to its collaboration partners for the development of drugs using its ENHANZE platform.Halozyme now has eight marketed partnered drugs based on this technology.Halozyme currently earns royalties on sales of various commercial products by its partners. The ENHANZE platform was developed based on the company’s patented recombinant human hyaluronidase enzyme (rHuPH20).The company’s commercial portfolio of products include — Hylenex Recombinant and Xyosted, with the latter acquired from Antares Pharma in 2022. Incremental sales from Xyosted have been driving top-line growth.Halozyme derives the majority of its revenues from royalties on sales of partnered drugs. The company generated total revenues of $1.02 billion in 2024, up 22% year over year. This marked the first time that the company has managed to breach the $1 billion mark in total revenues. Bottom LineWhile anyone can invest, building a lucrative investment portfolio takes research, patience, and a little bit of risk. If you had invested in Halozyme Therapeutics ten years ago, you're probably feeling pretty good about your investment today.According to our calculations, a $1000 investment made in September 2015 would be worth $3,925.95, or a gain of 292.59%, as of September 18, 2025, and this return excludes dividends but includes price increases.The S&P 500 rose 231.64% and the price of gold increased 208.55% over the same time frame in comparison.Analysts are forecasting more upside for HALO too.Halozyme's second-quarter earnings and revenues beat estimates. The company has collaboration deals related to its ENHANZE technology with several large pharma companies that generate royalties and milestone payments, which are driving the top line. Robust demand for the subcutaneous formulation of J&J's Darzalex and Roche's Phesgo is boosting royalties and the top line. The momentum is likely to continue in the second half. Halozyme is also focused on signing new collaboration deals to aid growth. However, blockbuster drugs like Herceptin and Rituxan, which utilize ENHANZE technology, are now facing biosimilar competition, resulting in decreased revenues from royalties. High dependence on partners for revenues in the form of royalties and collaborative agreements is a woe. Any deal termination will hurt the stock.The stock is up 6.58% over the past four weeks, and no earnings estimate has gone lower in the past two months, compared to 5 higher, for fiscal 2025. The consensus estimate has moved up as well.Beyond Nvidia: AI's Second Wave Is HereThe AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.See "2nd Wave" AI stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks